Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

House dust mite allergy immunotherapy - ALK-Abello

Next Previous
Drug Profile

House dust mite allergy immunotherapy - ALK-Abello

Alternative Names: ACARIZAX; ALK HDM; ALK Mite Tablet; HDM AIT; HDM SLIT drops - ALK-Abello; HDM SLIT extract - ALK-Abello; HDM SLIT tablet- ALK-Abello; House dust mite extract - ALK-Abello; House dust mite SLIT drops - ALK-Abello; House dust mite SLIT One Dermatophagoides mixture - ALK-Abello; House dust mite SLIT tablet - ALK-Abello; MITICURE; Mitizax; MK-8237; ODACTRA; SCH-900237; Sensimune; SLITONEULTRA-HDM; SQ®HDM SLIT-tablet - ALK-Abello; TO-203

Latest Information Update: 19 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ALK-Abello
  • Developer Abbott Laboratories; ALK-Abello; Merck & Co; Seqirus; Torii Pharmaceutical
  • Class Allergens; Allergy immunotherapies; Anti-inflammatories; Antiallergics; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic asthma; Allergic rhinitis; Allergic rhinoconjunctivitis
  • Phase III Atopic dermatitis; Rhinoconjunctivitis

Most Recent Events

  • 14 Aug 2026 National Institute for Health and Care Excellence (NICE) has recommends House dust mite allergy immunotherapy for Allergic rhinitis (In children)
  • 02 Mar 2026 Efficacy data from phase III MATIC trial in Allergic rhinitis presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2026)
  • 17 Sep 2025 ACARIZAX® SLIT-tablet licensed to GeneScience Pharmaceutical in China

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top